Gilead study of tenofovir

Gilead paid doc­tors to re­cruit 30 HIV pa­tients in Los Angeles, New York, Phil­adelphia and Pa­lo Alto for pre­lim­in­ary stud­ies to see how it worked in hu­mans. The tri­al found that teno­fo­vir, the mod­i­fied for­mu­la­tion, “had great­er an­ti­vir­al po­tency” at a frac­tion of the dose.